Analysis on the Application of Oral Lipid-Regulating Drugs in Chinese PLA General Hospital During 2016-2018

GUO Ruijie; XIN Haili

doi:10.14009/j.issn.1672-2124.2020.10.025

您当前的位置：

首页 >

文章列表页 >

Analysis on the Application of Oral Lipid-Regulating Drugs in Chinese PLA General Hospital During 2016-2018

更新时间：2022-10-08

- Analysis on the Application of Oral Lipid-Regulating Drugs in Chinese PLA General Hospital During 2016-2018
- Vol. 20, Issue 10, Pages: 1253-1254(2020)
- 作者机构：
  
  中国人民解放军总医院医疗保障中心药剂科门诊药局
- 作者简介：
- 基金信息：
- DOI：10.14009/j.issn.1672-2124.2020.10.025
  CLC： R95
- Published：2020，
扫描看全文
[1]郭瑞杰,辛海莉.2016—2018年中国人民解放军总医院口服调节血脂药使用情况分析[J].中国医院用药评价与分析,2020,20(10):1253-1254+1259.

GUO Ruijie, XIN Haili. Analysis on the Application of Oral Lipid-Regulating Drugs in Chinese PLA General Hospital During 2016-2018. [J]. 20(10):1253-1254(2020)
[1]郭瑞杰,辛海莉.2016—2018年中国人民解放军总医院口服调节血脂药使用情况分析[J].中国医院用药评价与分析,2020,20(10):1253-1254+1259. DOI： 10.14009/j.issn.1672-2124.2020.10.025.

GUO Ruijie, XIN Haili. Analysis on the Application of Oral Lipid-Regulating Drugs in Chinese PLA General Hospital During 2016-2018. [J]. 20(10):1253-1254(2020) DOI： 10.14009/j.issn.1672-2124.2020.10.025.

摘要

目的:了解2016—2018年中国人民解放军总医院（以下简称"我院"）口服调节血脂药使用情况及变化趋势

为临床合理用药和管理提供参考依据。方法:通过医院信息系统

提取2016—2018年我院口服调节血脂药相关使用数据

对各类药品的销售金额、用药频度（defined daily dose system

DDDs）、限定日费用（defined daily cost

DDC）和药品销售金额排序（B）/DDDs排序（A）的比值等进行回顾性分析。结果:2016—2018年我院口服调节血脂药中

他汀类药物的销售金额排序始终居首位

阿托伐他汀、瑞舒伐他汀和匹伐他汀的销售金额排序、DDDs排序连续3年居前3位;普罗布考和辛伐他汀的销售金额、DDDs呈逐年降低趋势;普伐他汀和阿昔莫司的销售金额、DDDs相对比较平稳;依折麦布的销售金额、DDDs在2018年呈明显升高趋势

其排序均由第8位升至第4位;非诺贝特、氟伐他汀和多廿烷醇的销售金额排序、DDDs排序一直居后3位。3年来

我院口服调节血脂药的DDC呈逐年降低趋势;多廿烷醇的DDC排序均居首位。普罗布考的B/A <1

阿昔莫司的B/A> 1

其他调节血脂药的B/A为1。结论:我院口服调节血脂药的使用情况基本合理

符合当前指南推荐的用药原则。

Abstract

OBJECTIVE: To investigate the application and its trend of oral lipid-regulating drugs in China PLA General Hospital（ hereinafter referred to as"our hospital"） during 2016-2018

so as to provide references for clinical rational drug application and management. METHODS: Through Hospital Information System

data related to oral lipidregulating drugs in our hospital during 2016-2018 were extracted and retrospectively analyzed in terms of consumption sum

defined daily dose system（ DDDs）

defined daily cost（ DDC） and ratio of sequence of consumption sum（ B）/sequence of DDDs（ A）. RESULTS: Among the oral lipid-regulating drugs in our hospital during 2016-2018

the consumption sum of statins had always ranked the first

the top 3 drugs ranked by consumption sum and DDDs in the continuous 3 years were respectively atorvastatin

rosuvastatin and pivastatin; the consumption sum and DDDs of probucol and simvastatin decreased year by year; the consumption sum and DDDs of pravastatin and acipimox were relatively stable; the consumption sum and DDDs of ezetimibe showed significantly increasing trend in 2018

and its ranking rose from 8 th to 4 th; the consumption sum and DDDs of fenofibrate

fluvastatin and policosanol had always been the bottom 3. In the past three years

the DDC of oral lipid-regulating drugs in our hospital decreased year by year; the DDC of policosanol ranks first. The B/A of Probucol was < 1

acipimox was > 1

and the B/A of other lipid-regulating drugs were 1. CONCLUSIONS: The application of oral lipid-regulating drugs in our hospital is basically rational

which meets the medication principle of current guideline recommendation.

关键词

调节血脂药销售金额用药频度限定日费用

Keywords

Lipid-regulating drugsConsumption sumDefined daily dose systemDefined daily cost

references

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Investigation and Analysis of Application of Tamoxifen and Toremifene in the Treatment of Breast Cancer in 15 Grade Ⅲ,Level A Hospitals in Shanghai from 2015 to 2019

Application of Anti-HIV Drugs in Outpatient Department of Our Hospital from 2016 to 2020

Analysis of Use of New Anti-Tumor Drugs in the First Affiliated Hospital of University of Science and Technology of China from 2017 to 2020

Analysis of Application of Hospital Preparations in Sichuan Provincial People’s Hospital from 2017 to 2019

Application of Endocrine Therapy Drugs for Breast Cancer in 6 Regions of China from 2011 to 2017

Related Author

WANG Mengmeng

FAN Jiazuan

DU Qiong

YU Bo

ZHAI Qing

ZHENG Yonghong

GAO Aiping

HUANG Can

Related Institution

Dept.of Pharmacy,Fudan University Shanghai Cancer Center

Dept.of Oncology,Shanghai Medical College, Fudan University

Dept.of Pharmacy, Tongren Hospital,Shanghai Jiao Tong University School of Medicine

Dept. of Pharmacy, Beijing You’an Hospital, Capital Medical University

Dept.of Pharmacy,the First Affiliated Hospital of University of Science and Technology of China/Anhui Provincial Hospital

⁰